Find your next paid study

State University of New York at BuffaloNCT05127616

~$10 – $750

Actual pay is set by the research site.

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residua…

Pituitary Adenoma

~$150 – $3,000

Actual pay is set by the research site.

Mayo ClinicNCT07456878

Pancreatic AdenocarcinomaHomologous Recombination Deficiency

A Phase 2 Trial of Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

The purpose of this research study is to see the effects (good or bad) of Lorigerlimab on patients with pancreatic adenocarcinoma (PDAC) and homologous recombi…

University of MiamiNCT07565155

~$75 – $2,000

Actual pay is set by the research site.

Solid Tumor CancerLocally AdvancedMetastatic Solid Tumors+5 more

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and …

Avenzo Therapeutics, Inc.NCT07038343

~$150 – $4,200

Actual pay is set by the research site.

Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+3 more

A Phase 2 Randomized Trial of Remodeling Intestinal Microbiota Using Fecal Microbiome Transplant (FMT) Among Recipients of Chimeric Antigen Receptor T Cells (CAR T)

This phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after …

~$75 – $2,000

Actual pay is set by the research site.

Advanced CancerAdvanced Solid Tumors

A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tol…

Shanghai Allink Biotherapeutics Co., Ltd.NCT06656390

~$150 – $4,200

Actual pay is set by the research site.

Adenocarcinoma of the Pancreas

Phase I/II Study of Neoadjuvant mFOLFIRINOX in Combination With Peri-operative Oral Hydroxychloroquine (FHQ) in Subjects With Resectable Adenocarcinoma of the Pancreas.

This will be a phase I/II trial examining the safety and tolerability of pre-operative mFOLFIRINOX in combination with peri-operative oral hydroxychloroquine (…

West Virginia UniversityNCT04911816

~$150 – $3,000

Actual pay is set by the research site.

Observational

A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients

Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT…

Head and Neck CancersBreast CancerThoracic Cancers+3 more

Varian, a Siemens Healthineers CompanyNCT06681233

~$10 – $1,125

Actual pay is set by the research site.

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

~$150 – $4,500

Actual pay is set by the research site.

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherap…

Bristol-Myers SquibbNCT07221149

~$75 – $3,000

Actual pay is set by the research site.

Observational

Exploring Pain Modulation Mechanisms: A Study of TMS and Repeated Conditioned Pain Modulation

Conditioned pain modulation (CPM) is the behavioral measure of diffuse noxious inhibitory control (DNIC), an endogenous pain inhibitory pathway in which pain i…

Healthy Adult

Priyanka Rana, PT, MPT, PhDNCT06726018

~$10 – $1,125

Actual pay is set by the research site.

Low-grade GliomaAdvanced Solid Tumor

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade gli…